NGNE Valuation

Neurogene Inc

Add to Watchlist

Advanced Chart

20.060

-0.34(-1.667%)1D

NGNE Relative Valuation

NGNE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NGNE is overvalued; if below, it's undervalued.

Historical Valuation

Neurogene Inc (NGNE) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.14. The fair price of Neurogene Inc (NGNE) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：20.06

Fair

-4.10

Trailing

Forward

0.00

EV/EBITDA

Neurogene Inc. (NGNE) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.

-0.57

EV/EBIT

Neurogene Inc. (NGNE) has a current EV/EBIT of -0.57. The 5-year average EV/EBIT is -2.79. The thresholds are as follows: Strongly Undervalued below -7.97, Undervalued between -7.97 and -5.38, Fairly Valued between -0.20 and -5.38, Overvalued between -0.20 and 2.39, and Strongly Overvalued above 2.39. The current Forward EV/EBIT of -0.57 falls within the Historic Trend Line -Fairly Valued range.

0.00

Neurogene Inc. (NGNE) has a current PS of 0.00. The 5-year average PS is 120.65. The thresholds are as follows: Strongly Undervalued below -525.48, Undervalued between -525.48 and -202.41, Fairly Valued between 443.72 and -202.41, Overvalued between 443.72 and 766.79, and Strongly Overvalued above 766.79. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-3.34

P/OCF

Neurogene Inc. (NGNE) has a current P/OCF of -3.34. The 5-year average P/OCF is -5.04. The thresholds are as follows: Strongly Undervalued below -9.45, Undervalued between -9.45 and -7.25, Fairly Valued between -2.84 and -7.25, Overvalued between -2.84 and -0.63, and Strongly Overvalued above -0.63. The current Forward P/OCF of -3.34 falls within the Historic Trend Line -Fairly Valued range.

-3.14

P/FCF

Neurogene Inc. (NGNE) has a current P/FCF of -3.14. The 5-year average P/FCF is -4.45. The thresholds are as follows: Strongly Undervalued below -8.27, Undervalued between -8.27 and -6.36, Fairly Valued between -2.54 and -6.36, Overvalued between -2.54 and -0.63, and Strongly Overvalued above -0.63. The current Forward P/FCF of -3.14 falls within the Historic Trend Line -Fairly Valued range.

Neurogene Inc (NGNE) has a current Price-to-Book (P/B) ratio of 1.12. Compared to its 3-year average P/B ratio of 2.04 , the current P/B ratio is approximately -45.26% higher. Relative to its 5-year average P/B ratio of 2.04, the current P/B ratio is about -45.26% higher. Neurogene Inc (NGNE) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -20.35%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -20.35% , the current FCF yield is about -100.00% lower.

1.12

P/B

Median3y

2.04

Median5y

2.04

-24.81

FCF Yield

Median3y

-20.35

Median5y

-20.35

Competitors Valuation Multiple

The average P/S ratio for NGNE's competitors is 0.00, providing a benchmark for relative valuation. Neurogene Inc Corp (NGNE) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Galectin Therapeutics Inc

Lyell Immunopharma Inc

Autolus Therapeutics PLC

Loss

327.36M

Performance Decomposition

Market capitalization of NGNE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NGNE in the past 1 year is driven by Unknown.